Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations

NCT01609543 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01609543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01609543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2012
Completion date
January 31, 2015
Enrollment
62 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer